TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area Under Curve From 0 to tz Hours (AUC0-tz) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Concentration (Cmax) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plateau Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weight of protective pads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Reporting Condomless Anal Sex
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Occurrence of Sexually Transmitted Infections (STIs)
Endpoint domain: Adverse events/effects
Primary endpoint: self-inflicted potentially injurious behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Total calcium score measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response to treatment (25% reduction in ANC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Development of joint pain or joint swelling
Endpoint domain: Adverse events/effects
Primary endpoint: AUC from Time Zero to Infinity (AUCinf) of AMG 510
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Past 7-day Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Stomach Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Mortality of Stomach Cancer
Endpoint domain: Mortality/survival
Primary endpoint: number of patients with complete and partial remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival without recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change in LDL-C from baseline to Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients reducing LDL-C by 10% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: End of action (time until blood glucose concentration above 8.3 mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of post-operative infections
Endpoint domain: Adverse events/effects
Primary endpoint: Level of Applied Growth Factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excretion of radioactivity in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Excretion of radioactivity in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the serial FEV1(L)-time curve (AUC0-12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1(L) measured prior to dosing on the last day of treatment (trough FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Regression rate of endometrial polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relapse rate of endometrial polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Relative solid stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recanalization of nasolacrimal duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: renal function measured by eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 1 year Progression Free Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: 6 months survival after radiotherapy
Endpoint domain: Mortality/survival
Primary endpoint: Thickness of the core and quadriceps muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Daily life activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: American Shoulder and Elbow Surgeon (ASES) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Treatment-emergent Adverse Event (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with good Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiopulmonary Fitness: Peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response as assessed by Cheson criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Depression symptoms as assessed by PROMIS Depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Anxiety symptoms as assessed by PROMIS Anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recovery of ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep vein thrombosis rate post-treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline to Week 15 in Weekly Mean Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sample Adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of visual analogue scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: dopamine receptor availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of subjects correctly responding to survey questions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mesothelial cell shedding and apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toronto Alexithymia Scale-20 (TAS-20)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Levels of Emotional Awareness Scale (LEAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Net clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRSA nasal carriage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decisional conflict related to HCV treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in scale for the assessment and rating of ataxia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Spinocerebellar Ataxia Functional Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Composite Cerebellar Functional Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bone Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in Central Corneal Endothelial Cell Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of CV deaths plus thrombotic events
Endpoint domain: Mortality/survival
Primary endpoint: Vessel density of the choriocapillary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical lipid and research protein measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summary score of psychological distress/depression at age 65
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite measure of cognition at age 65
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Social Adaptive Functions Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Multnomah Community Ability Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Global Assessment of Functioning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: All device- and procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Total Postoperative Opioid Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood flow estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Trunk Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering ocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of e-GAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heartburn Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of TAS-114/capecitabine
Endpoint domain: Adverse events/effects
Endpoint subdomain: Dose Limiting Toxicity (DLT)
Primary endpoint: Percentage of Participants With at Least One Event of NYHA Class III or IV Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With at Least One LVEF Significant Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gestational weight gain exceeding recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in high-density lipoprotein (HDL) Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in low-density lipoprotein (LDL) Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose (MTD) of 5-fluoro-2-deoxycytidine (FdCyd)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Maximum Standardized Update Value (SUVmax) in Brown Adipose Tissue FDG Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Asthma Symptoms and Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of myocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of myositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of rhabdomyolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Angina pectoris symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin flush response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: levels of biochemical serum markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0_infobs: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value of the Last Quantifiable Concentration for Dexlansoprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Sat O2 achieved (in %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Confirmed response (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of insulin aspart concentration (AUC IAsp, 0-16h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum insulin aspart concentration (Cmax IAsp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intensive Care Unit Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change of myocardial infarction area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean T Cavg25 Following Meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of varicose veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ASIiAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: American Shoulder and Elbow Surgeon Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Purchase of sugar-sweetened beverages
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: EBP beliefs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: operative time in minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: postoperative pain using visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postoperative complications measured by clinical examination and anal sphincter manometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion rate of cholecalciferol deficiency correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ward days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Discharge status
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: composite events composed of all-cause mortality and/or major adverse cardiac and cerebrovascular events (MACCE)
Endpoint domain: Mortality/survival
Primary endpoint: myocardial injury in non-cardiac surgery (MINS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major Adverse Cardiovascular Event Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major Adverse Limb Event Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: workdays lost by adults
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: school days lost by children
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Accuracy of Clearblue pregnancy test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Decrease in number of evacuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Vaccine Regime
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms During the Vaccine Regime
Endpoint domain: Adverse events/effects
Primary endpoint: Magnitude and Breadth of Neutralizing Antibody Response Against Autologous Viral Isolates 2 Weeks After the Fourth Vaccinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Fail to Complete the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Range of Motion (ROM) of elbow flexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin-dependency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes of calcification score of coronary arteries and aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incisional pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain morphological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Mu-opioid Receptor Binding Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of disease signal to measurement noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on working memory task (N-Back)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Glucose variability indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: number, severity, and type of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: change in clinical laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Therapeutic Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for pulmonary surfactant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Abnormal PAT Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypothermia rate
Endpoint domain: Adverse events/effects
Primary endpoint: Willingness to Enroll
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Actual Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability of a virtual deployment trauma assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of partners agreeing to attend VCT
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Repeat dose pharmacokinetics of morphine and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Everolimus with radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Everolimus with radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Flanker Inhibitory Control and Attention Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Dimensional Change Card Sort Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With a Prostate-specific Antigen Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neural responses to emotional stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vaspin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resistin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum asymmetric dimethyl arginine (ADMA) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inspiratory effort quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of OCB IgG negative subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Therapy effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver status by liver biopsy (steatosis and fibrosis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of participants with treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of RAD001 in combination with PKC412
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Centre for Epidemiologic Studies Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Short-Form-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The State-Trait Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Patients Who Experience a Confirmed Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time in Weeks to Discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of volume of the Vascular Malformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Capture rate of convulsive seizure events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of adverse events and severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Doubling of serum creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 50% reduction in GFR (estimated by MDRD equation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to 99% Inhibition of Serum Thromboxane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average Corneal Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients diagnosed with anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes